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Journal of the American Heart Association
CONTEMPORARY REVIEW

Pathophysiology of Delayed Cerebral
Ischemia After Subarachnoid Hemorrhage:
A Review
William S. Dodd , BS; Dimitri Laurent , MD; Aaron S. Dumont, MD; David M. Hasan , MD;
Pascal M. Jabbour , MD; Robert M. Starke, MD; Koji Hosaka, PhD; Adam J. Polifka, MD; Brian L. Hoh, MD;
Nohra Chalouhi , MD
ABSTRACT: Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer subarachnoid hemorrhage.
Treatment options are limited and often ineffective despite many years of investigation and clinical trials. Modern advances in
basic science have produced a much more complex, multifactorial framework in which delayed cerebral ischemia is better understood and novel treatments can be developed. Leveraging this knowledge to improve outcomes, however, depends on a
holistic understanding of the disease process. We conducted a review of the literature to analyze the current state of investigation into delayed cerebral ischemia with emphasis on the major themes that have emerged over the past decades. Specifically,
we discuss microcirculatory dysfunction, glymphatic impairment, inflammation, and neuroelectric disruption as pathological
factors in addition to the canonical focus on cerebral vasospasm. This review intends to give clinicians and researchers a
summary of the foundations of delayed cerebral ischemia pathophysiology while also underscoring the interactions and interdependencies between pathological factors. Through this overview, we also highlight the advances in translational studies
and potential future therapeutic opportunities.
Downloaded from http://ahajournals.org by on August 18, 2021
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A

neurysmal subarachnoid hemorrhage (aSAH) is a
particularly devastating event; the case-fatality rate
is ≈40% to 50% and many survivors remain dependent on others for activities of daily living.1–4 The disproportionate impact on people younger than 65 years old
relative to ischemic stroke also imposes a burden on the
healthcare system and society through increased costs
and loss of productive life-years.5 The prognosis for patients with SAH is heavily influenced by the development
of delayed cerebral ischemia (DCI),1,6 but adequate treatments to prevent DCI remain elusive.7 Advances in critical
care management and refinement of surgical techniques
have helped the overall morbidity and mortality from
aSAH decline slightly over the past few decades8; however, translationally focused scientific inquiry in this field
remains vital to paradigm-shifting discoveries.

The conceptual framework of DCI after SAH has
undergone vast transformations over the last century.
Ischemic cerebral lesions were documented after aneurysmal SAH as far back as the 1940s,9 around the same
time that researchers noted relationships between
hemorrhage, delayed infarctions, and cerebral vasospasm.10,11 The associations between these phenomena, especially the time course of onset, led to the belief
that vasospasm was the singular cause of DCI (also referred to as delayed ischemic neurological deficits).3,12–14
Widespread use of the terms “clinical vasospasm” and
“symptomatic vasospasm” reflect the conceptualization
of cerebral ischemia after SAH as consequent function
of “angiographic vasospasm” rather than a distinct, multifactorial entity. This paradigm began to shift in the early
21st century as it became increasingly apparent that the
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ischemic areas did not necessarily correlate with the
distribution of spastic arteries and DCI/hypoperfusion
could occur without the presence of vasospasm.15–18 The
CONSCIOUS (Clazosentan to Overcome Neurological
Ischemia and Infarction Occurring After Subarachnoid
Hemorrhage) trials19–21 were foundational in transforming the understanding of DCI pathology by demonstrating that prevention of vasospasm does not necessarily
reduce all-cause mortality or DCI. The renewed interest
in clinical investigation also prompted a unified definition
of DCI22:
The occurrence of focal neurological impairment … or a decrease of at least 2
points on the Glasgow Coma Scale … This
should last for at least 1 hour, is not apparent immediately after aneurysm occlusion,
and cannot be attributed to other causes
by means of clinical assessment, CT or MRI
scanning of the brain, and appropriate laboratory studies.
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This definition is now widely used in clinical studies, facilitating efficient investigation and reliable meta-analysis.
The SAHIT (Subarachnoid Hemorrhage International
Trialists) Repository has also aided the development of
well-
designed, harmonized clinical trials by identifying
critical data points.23 Since then, further study into the
underlying pathophysiology has revealed previously elusive effects on the microvasculature and inflammatory
milieu associated with DCI that can inform future clinical
trials and drug development.24,25
DCI is currently understood as a multifactorial process that evolves over time. The first 24 to 48 hours
after ictus are referred to as the early brain injury
phase, largely characterized by the sequelae of increased intracranial pressure and transient global
ischemia during ictus. Cerebral edema, blood-
brain
barrier (BBB) disruption, sympathetic nervous system
activation, autoregulatory failure, microthrombosis,
spreading depolarizations (SDs), and inflammation
have all been observed during this period.26 Over time,
the extravasated blood begins to aggravate and modulate the same core factors, culminating in the clinical
manifestation of delayed cerebral ischemia around 4 to
10 days post-SAH.12,27
The purpose of this review is to both examine the
current state of investigation into DCI as well as analyze the underlying mechanisms of the disease. In addition, we review novel therapeutic strategies as they
relate to the novel insights into DCI pathophysiology.
The pathological components of DCI are intimately interconnected, but for the purposes of this review we
discuss 3 overarching areas: vascular dysfunction,
inflammation, and cortical spreading depolarizations.

Pathophysiology of Delayed Cerebral Ischemia

For each topic we review the foundational studies
demonstrating a role in DCI, the most recent advances
within the field, and therapeutic strategies gleaned
from those developments.

VASCULAR DYSFUNCTION
Inability of cerebral perfusion to match metabolic demand is the ultimate cause of DCI; thus any pathological event that decreases perfusion or increases
metabolic demand can contribute to DCI. In this section, we focus on the former, specifically the mechanisms of inadequate vascular response that increase
susceptibility to DCI.
Because of the lasting influence of the vasospasm-
centered approach to DCI research, many vasodilatory
or otherwise vasoactive agents have been tested in patients with SAH (Table). Triple H therapy (hypertension,
hypervolemia, and hemodilution) or permissive hypertension alone are intended to mechanically vasodilate
by intravascular volume expansion but are prone to
cardiopulmonary and renal complications.28,29 A meta-
analysis of Triple H therapy found that, in addition to
methodological issues in standardizing treatments,
there was no effect on DCI.30 As mentioned previously,
the CONSCIOUS trials demonstrated that inhibition of
the vasoconstrictive endothelin-1 pathway decreases
vasospasm but has no effect functional outcomes.19–21
Another phase 3 clinical trial with clazosentan, a selective endothelin-1 receptor anatagonist, has been announced since the end of CONSCIOUS-3, the REACT
trial.31 Unlike the CONSCIOUS trials that used a composite primary endpoint (all-cause mortality, DCI, or
need for vasospasm rescue therapy), REACT will focus
on the development of DCI. Additionally, the REACT
trial will use the higher of the 2 clazosentan doses administered in CONSCIOUS-3 because of more support for possible efficacy. The MASH-2 (Magnesium
for Aneurysmal Subarachnoid Haemorrhage-
2) trial
showed intravenous magnesium sulfate, putatively acting through inhibition of voltage-gated calcium channels,32 is also not effective for improving outcomes.33
Oral administration of the dihydropyridine-type calcium
channel blocker nimodipine is the only treatment with
consistent, high-quality evidence for decreasing DCI34
and is now standard of care in patients with aSAH, although these results are principally driven by 1 large
trial.35 Importantly, those early studies showed oral nimodipine reduces DCI and improves outcomes without
affecting vasospasm,36,37 suggesting nimodipine may
have important vessel-independent effects. A recent
trial (NEWTON [Nimodipine Microparticles to Enhance
Recovery While Reducing Toxicity After Subarachnoid
Hemorrhage]) of intraventricular nimodipine administration found no improvements over standard oral administration.38 These clinical trials clearly demonstrate that

J Am Heart Assoc. 2021;10:e021845. DOI: 10.1161/JAHA.121.0218452

Dodd et al

Pathophysiology of Delayed Cerebral Ischemia

Table 1. Summary of Major Clinical Trials and Meta-Analyses
No. Patients Included in Trial or
Meta-A nalysis

Candidate

Mechanism

Clazosentan19–21 (IV)

Endothelin-1 receptor antagonist.

CONSCIOUS-2: 1147 total (764
treatment/383 placebo)
CONSCIOUS-3: 571 total (188 high-
dose/194 standard dose/189 placebo)

Summary of Findings
Clazosentan treatment (5 or
15 mg/h) does not improve
outcomes after aSAH.
Possible increase in pulmonary
complications, anemia, and
hypotension

Magnesium sulfate33 (IV)

Inhibition of voltage-gated calcium
channels, N-methyl-D-aspartate
receptors, & glutamate release

Magnesium for Aneurysmal
Subarachnoid Haemorrhage-2: 1201
total (604 treatment/597 placebo)

Intravenous magnesium sulfate
therapy does not improve outcomes
after aSAH

Simvastatin39,40 (oral)

β-Hydroxy β-methylglutaryl-CoA
reductase inhibition, but has important
pleiotropic effects including improved
endothelial function and decreased
platelet activation

Simvastatin in Aneurysmal
Subarachnoid Haemorrhage: 809 total
(391 treatment/412 placebo)
High-Dose Simvastatin for Aneurysmal
Subarachnoid Hemorrhage: 255 total
(124 high dose/131 standard dose)

Simvastatin (40 or 80 mg/d) does
not improve short-or long-term
outcomes after aSAH

Tirilazad41 (IV)

Free radical scavenging and cell
membrane stabilization

Meta-Analysis: 3821 total across 5
double-blind, placebo-controlled trials

Tirilazad does not reduce mortality
or improve outcomes after aSAH

Cilostazol42 (oral)

Phosphodiesterase enzyme3 inhibition,
leading to increased PKA activity.
PKA relaxes vascular smooth muscle
and inhibits platelet activation through
multiple pathways

Meta-Analysis: 543 total across 5
studies

Cilostazol reduced “symptomatic
vasospasm” and improved
outcomes after aSAH; however,
the component studies included in
the meta-analysis were small and
mostly not placebo controlled. A
larger randomized controlled trial is
needed

Calcium-channel
blockers34,35 (including
oral nimodipine)

Inhibition of L-t ype calcium channels

Meta-Analysis: 3361 total across
16 trials; 6 trials specifically for oral
nimodipine (969 patients total)

Oral nimodipine reduces incidence
of poor outcomes and delayed
cerebral ischemia. Importantly, the
results are driven primarily by a large
single-center study
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aSAH indicates aneurysmal subarachnoid hemorrhage; CONSCIOUS, Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After
Subarachnoid Hemorrhage; and PKA, protein kinase A.

targeting vascular dysfunction through vasodilation
alone is not sufficient to reduce DCI.
In this article we highlight the clinical and animal
studies that elucidated the fundamental processes
of vascular dysfunction after SAH and those that expanded the understanding to include microvessels, arterioles, paravascular spaces, and lymphatic vessels.
We also discuss the recently discovered mechanisms
of vascular dysfunction that can be leveraged in the
development of novel therapies.

Inciting Factors of Vascular Dysfunction
The first physiologic insult after SAH is a transient
global ischemia as intracranial pressure approaches
mean arterial pressure.43,44 This ischemic episode can
trigger vascular dysfunction even before the toxic effects of hemoglobin are realized (Figure 1). First, the
process is initiated through an induction of the sympathetic nervous system,45 often referred to as the
“sympathetic surge” or “catecholamine surge.” Initial
activation involves both ischemic injury to the hypothalamus46 as well as compression of the brain stem.47
Plasma catecholamines remain elevated for several
days post-SAH45 and high concentrations predict poor

outcomes,48,49 perhaps involving injury to extracerebral
organs.50 A recent study by Takemoto et al demonstrated that attenuation of the sympathetic response
via bilateral renal denervation decreases vasospasm
and cerebral edema in rats.51 Behavioral and neurological responses were not affected by this intervention,
indicating that reducing sympathetic nervous system
activation alone is not sufficient to prevent neurological
deficits. Separate from sympathetic nervous system
activation, transient global ischemia causes endothelial injury and BBB disruption as well. Endothelial injury
and even apoptotic cell death have been reported to
occur within the first 24 hours post-SAH,52,53 which
disrupts the BBB and promotes coagulation by exposing subendothelial collagen.54 BBB disruption can
be measured indirectly in humans, via abnormal tissue enhancement on contrast computed tomography
or isotope scintigraphy studies.55 Endothelial injury,
BBB disruption, and the resulting vasogenic edema
are all important avenues for future investigation, as
all are predictive of patient outcome.55,56 Yet another
consequence of acute global ischemia is stimulation
of the endothelin-1 pathway. Using a primate model,
Pluta et al found that hypoxia, not oxyhemoglobin, was
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Figure 1. Vascular dysfunction after subarachnoid hemorrhage.
Transient global ischemia and free hemoglobin toxicity are the ultimate sources of vascular dysfunction leading to microthrombosis
and vasospasm. Perturbation of the NO pathway is a pivotal mechanism connecting vascular dysfunction to inflammation and cortical
spreading ischemia. The glymphatic system and meningeal lymphatic vessels are also emerging as a possible mediator of delayed
cerebral ischemia. CBF indicates cerebral blood flow; CSF, cerebrospinal fluid; ICP, intracranial pressure; ROS, reactive oxygen
species; SAH, subarachnoid hemorrhage; and SDs, spreading depolarizations.

responsible for the SAH-induced increase in endothelin-1 expression.57 Some early clinical studies into this
pathway found that plasma endothelin-1 concentrations correlated with DCI58 and endothelin-1 inhibition
reversed SAH-associated reductions in cerebral blood
flow.59 So, although endothelin-
1 antagonism alone
does not prevent DCI, it is still important to consider
the acute phase sequelae of increased intracranial
pressure that occur independently of hemoglobin-
mediated vascular dysfunction.
Management of elevated intracranial pressure and hydrocephalus is also significant to outcomes after SAH.
Aggressive clearance of cerebrospinal fluid (CSF)
through continuous external ventricular drainage is a
conceptually tempting approach to lower intracranial
pressure and accelerate clearance of spasmogenic
blood products; however, this strategy does not lead
to decreased DCI.60 Further, intermittent CSF drainage and rapid external ventricular drainage weans are
associated with fewer complications and shorter intensive care unit length of stay.60– 62 Lumbar drainage
has emerged as an alternative to external ventricular
drainage that has the potential to provide the benefits

of CSF drainage, including reduced vasospasm, with
a lower rate of complications.63,64 There is an ongoing
trial assessing neurapheresis using a lumbar drainage
filtration system as an intervention to reduce DCI.65
These approaches demonstrate the ability of refined
techniques to not only prevent complications but actively suppress DCI pathology as well.
Hemoglobin and other blood products remain sequestered until the erythrocytic membranes become
unstable and lyse, releasing oxyhemoglobin and
other vasoactive blood products. Oxyhemoglobin and
deoxyhemoglobin concentrations in the CSF peak
around day 7 post-
SAH in primates,66 roughly corresponding to the onset of secondary brain injury.
Even before the precise mechanisms were clarified,
the hypothesis that hemoglobin must be the primary
spasmogen was supported by reports that hematoma
evacuation prevents vasospasm in primates.67,68 A few
years later, purified oxyhemoglobin alone was shown
to induce a contractile response in canine cerebral arteries69 and later studies demonstrated this occurred
through the Rho/ROCK (Rho/Rho-
associated protein kinase) and PKC (protein kinase C) pathways.70
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Fasudil, an inhibitor of the Rho/ROCK pathway, has
been shown to reduce smooth muscle cell contraction,
reduce vasospasm, and improve clinical outcomes
after aSAH,71–73 but it is not approved for use by the
Food and Drug Administration or European Medicines
Agency. Cilostazol, a phosphodiesterase enzyme3 inhibitor that relaxes vascular smooth muscle and inhibits platelet activation,74 has also been shown to reduce
vasospasm and improve clinical outcomes in several
trials.42,75 Oxyhemoglobin is also a potent scavenger
of NO and reduces the availability of NO in the surrounding cerebral vasculature.76,77 Production of NO
is unable to compensate for this loss owing to a rise
in asymmetric dimethylarginine,78,79 an endogenous
nitric oxide synthase (NOS) inhibitor, and decreased
expression of endothelial-and neuronal-specific NOS
isoforms.80,81 The remaining NOS enzymes are also
damaged through oxidation of essential enzymatic cofactors by reactive oxygen species from hemoglobin
metabolism and local inflammation. This results in the
“NOS uncoupling” phenomenon whereby consumption of substrates L-
arginine and O2 is “uncoupled”
from NO production and instead results in superoxide
(O2⋅ −) generation.82 The presence of superoxide further
reduces NO bioavailability by reacting with the remaining NO to form peroxynitrite, a potent oxidizing agent.82
This perfect storm of vasoconstrictive, NO-depleting,
and reactive oxygen species-generating events after
SAH is central to the resulting vascular dysfunction
(Figure 1). This has been demonstrated experimentally by administration of NO-donors, which improved
cerebral hemodynamics in humans and non-humans
primates after SAH83,84; however, NO donors have little
translational potential owing to their adverse effects.83
Nonspecific antioxidant therapies are also ineffective
after SAH, demonstrated most clearly by the failure
of tirilazad to improve outcomes in a meta-analysis of
3821 patients.41 Interestingly, the clinical importance
and relative pathological contribution of the “NOS uncoupling” phenomenon is still not completely resolved,
as some studies report genetic knockout of endothelial
NOS in mice reduces vascular dysfunction after SAH
whereas others show phenotypes similar to wild-type
mice.85,86 In any case, future therapeutic application
must account for the complexities of the NOS pathway
and the context-dependent relationship between NOS
activation and NO bioavailability.

Microthrombosis and
Thromboinflammation
The NO-
cyclic guanosine monophosphate pathway
is central to preserving vascular homeostasis through
inhibition of platelet aggregation, leukocyte adhesion,
and smooth muscle cell proliferation in addition to
maintaining vasodilatory tone.87–90 The procoagulant

Pathophysiology of Delayed Cerebral Ischemia

effects of platelet aggregation and spasm within intraparenchymal arterioles, known as microthrombosis, has been an emerging area of intense research
because the incidence of microclots was shown
to correlate with DCI and clinical outcome.15,91–94
The endothelial protease ADAMTS13 normally represses platelet adhesion and thrombosis-
induced
inflammatory change through downregulation of von
Willebrand factor and P-selectin,95 making microvascular endothelial injury and ADAMTS13 dysregulation a potential link between microthrombosis and
pathological inflammation. Interestingly, decreased
ADAMTS13 activity and increased von Willebrand factor and P-selectin levels all predict the development
of DCI in patients with SAH,96–99 indicating thromboinflammation could be a clinically relevant therapeutic
target. Preclinical animal models have demonstrated
increased P-selectin expression in the microvascular
endothelium after SAH corresponding to areas of microthrombosis and neuronal cell death.100 Moreover,
treatment with a monoclonal anti-
P-
selectin antibody can reduce platelet-endothelial and leukocyte-
endothelial interations,101 suggesting P-selectin may be
a particularly suitable translational candidate to target
thromboinflammatory pathways. In addition to inciting
inflammation, activated platelets release glutamate,102
high concentrations of which can be neurotoxic.103 In
rats, glutamate levels in the CSF increase after SAH104
and there is an association between the location of
microthrombi and regional markers of excitotoxicity,105
indicating that the platelets within microthrombi could
be the source of toxic glutamate. Moreover, glutamate
and glutamate receptor activity are important regulators of the incidence and propagation of spreading
depolarizations (see “Spreading Depolarizations”). A
small, exploratory study in humans found extracellular glutamate concentrations rise after SAH, vary from
region to region, and may predict clinical outcome.106
Although more study is needed to confirm and expand
upon these findings, regional variation in glutamate levels could be explained by the presence of microthrombi
in areas that progress to delayed ischemia. Taken together, the available evidence strongly suggests microcirculatory dysfunction is central to DCI pathology and
an important area for more intense investigation.
There have been several trials aiming to reduce DCI
through inhibiting coagulation or platelet aggregation.
An important point to consider in the interpretation
of these studies is that the effects of anticoagulative
therapies on primary hematoma dissolution and prevention of secondary microthrombi cannot be readily discerned from one another. The design of these
protocols has to be done carefully as rebleeding of a
previously secured aneurysm and other hemorrhagic
complications are of primary concern with these
treatment modalities. Systemic anticoagulation with
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enoxaparin was shown to reduce DCI when given to
Hunt-Hess grade I–III patients,107 but this effect was
lost when the patient population was expanded to include more severe hemorrhage.108 Three retrospective
studies have also found that treatment with low-dose
intravenous heparin reduces DCI and improves functional outcomes.109–111 A rat model suggests that heparin may work through reducing the neuroinflammatory
response to SAH.112 Antiplatelet therapy has also been
tested through trials of aspirin, ozagrel hydrochloride,
dipyridamole, and ticlopidine. A meta-analysis (1385
patients total) of trials with these agents to date showed
a modest trend for better outcomes but also a possible increase in hemorrhagic complications.113 A recent
retrospective study found dual therapy of aspirin and
clopidogrel was associated with reduced incidence of
DCI and no increased risk of hemorrhagic complications,114 suggesting antiplatelet therapy could be useful with refined protocols. We are currently evaluating
the glycoprotein IIb/IIIa inhibitor tirofiban as one such
therapeutic. Compared with aspirin and clopidogrel,
tirofiban has a narrow therapeutic window, making it
an ideal antiplatelet agent for aSAH that may require
further neurosurgical interventions.115 After carefully
establishing safety and efficacy profiles in patients with
aSAH,116,117 a small trial showed promising reductions
in DCI without increase hemorrhagic complications.118
Larger clinical trials will be instrumental in definitive
evaluation of tirofiban and other antiplatelet therapies
as a treatment to prevent DCI.

Glymphatic and Meningeal Lymphatic
System
Lack of a lymphatic system was long believed to be
a unique characteristic of the central nervous system
until Louveau et al discovered lymphatic vessels within
the lining of the dural sinuses that interface with the
deep cervical lymph nodes.119 This discovery led to the
hypothesis that alterations in this novel meningeal lymphatic system and the central nervous system (CNS)
paravascular glymphatics contribute to the development of DCI. Even before the discovery of meningeal
lymphatics, it was demonstrated that cervical lymph
node blockage intensified oxidative stress after SAH.120
More recently, the meningeal lymphatic system was
found to be important for clearing the extravasated
erythrocytes from SAH and disruption of the lymphatic
vessels exacerbated the neuroinflammatory response,
especially microglial activation.121
Upstream from the meningeal lymphatics, paravascular glymphatic pathways lie next to penetrating arteries and constitute the direct interface between CSF and
parenchymal interstitial fluid.122 This pathway provides a
route for blood products from SAH to quickly penetrate
brain parenchyma and stimulate neuroinflammation.123

Pathophysiology of Delayed Cerebral Ischemia

Liu et al demonstrated that knockout of AQP4 (aquaporin 4), which is expressed in astrocytes at the interface of the paravascular pathways,124 worsens
outcome after SAH in rats.125 Their study indicates that
AQP4 may be involved in the impaired glymphatic flow
observed after SAH. Further, microthrombi formed in
the paravascular spaces after SAH can obstruct CSF
flow through the glymphatic system and contribute to
increased intracranial pressure.126 Administration of tissue plasminogen activator can clear the thrombi from
the paravascular space, increase cerebral blood flow
in the early brain injury phase, and improve neurological function in the delayed phase.123,126
Investigation into the paravascular space and meningeal lymphatics as a therapeutic target for DCI is
still in its infancy; however, the foundational studies
demonstrate an exciting avenue for future research.
The exposure of brain parenchyma to the toxic effects
of hemoglobin, hemoglobin metabolites, and other
blood products is clearly regulated by the paravascular
pathways. Strategies to limit the dissemination of toxic
metabolites into healthy tissue while permitting their
clearance through the lymphatic system may prove
valuable. Earlier research on fibrinolytic therapies presumed the therapeutic mechanism was clearing the
primary hematoma or microthrombi within penetrating arterioles and capillaries. Reinterpretation of these
studies with respect to the influence of paravascular
microthrombi could prove worthwhile.

Autoregulatory Failure
Cerebrovascular autoregulation is the process by
which cerebral blood flow is held constant over a
spectrum of perfusion pressures and blood gas partial
pressures.127,128 There are myogenic, neurogenic, metabolic, and endothelial factors contributing to cerebral
autoregulation129,130; thus, autoregulatory failure after
SAH is best conceptualized as a summative process
rather than an independent pathological mechanism.
Yundt et al found that patients with SAH, regardless
of the presence of vasospasm, have decreased cerebral blood volume compared to age-matched healthy
volunteers, whereas healthy volunteers subjected to
carotid compression display an increase in cerebral
blood volume.131 This study was important in that it
showed not just a diminished autoregulatory capacity
but a complete inversion of normal function. Another
similar study found diminished autoregulatory capacity, as measured by the transient hyperemic response,
predicted the development of DCI.132 This phenomenon has been replicated in recent years in a variety of
settings and using different imaging133,134 and vascular
reactivity stimuli,135 reaffirming the association between
diminished autoregulatory capacity and development
of DCI after SAH.
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The nature of autoregulation as an integrative process makes its relationship with DCI difficult to delineate through interventional studies. A phase II trial
found that pravastatin treatment reduced the duration
of impaired autoregulation and improved outcomes
compared to placebo.136 Overall, the current literature
supports autoregulation as a useful biomarker in clinical studies, but more research is required to determine
if autoregulatory disturbance is required for the development of DCI.

INFLAMMATION
Systemic Inflammation After SAH

Downloaded from http://ahajournals.org by on August 18, 2021

Inflammation is an extremely broad category of physiological and pathophysiological host responses to
infection and tissue injury.137 The severity of the inflammatory response after SAH predicts DCI and poor
outcomes. Retrospective studies find that lactate concentration, CRP (C-reactive protein) levels, erythrocyte
sedimentation rate, leukocyte count, negative nitrogen
balance, neutrophil-lymphocyte ratio, and systemic inflammatory response syndrome burden, all nonspecific
markers of inflammation, predict outcome following
SAH.138–145 Accordingly, systemic immunosuppression
with corticosteroids was one of the first experimental
treatments to prevent DCI.146,147 These and more recent
studies148 analyzing steroid treatment have shown no
effect on DCI and only a modest benefit toward functional outcome. The mixed effects of these small trials
are not sufficient to prove benefit or overcome the multitude of adverse side effects; thus, glucocorticoids are
not currently indicated in patients with SAH. Additional
clinical trials are also unlikely after a large randomized
controlled trial showed corticosteroid treatment increased mortality in the pathophysiologically related
setting of traumatic brain injury.149 Cyclosporine (discussed further in the next section) and nonsteroidal
anti-inflammatory drugs have also been used as general anti-inflammatories after SAH. A prospective observational study of 138 patients found that cumulative
nonsteroidal anti-inflammatory drug usage correlated
with better outcome (Glasgow Outcome Scale score
>3) and fewer cerebral infarctions.150 Another study of
178 patients found nonsteroidal anti-inflammatory drug
use led to lower mortality and shorter intensive care
unit stay, but the effects on DCI and functional outcome were nonsignificant.151 Aspirin alone has shown
no benefit to DCI or outcome.152,153 Overall, nonspecific
anti-inflammatory therapies have proven disappointing
for prevention of DCI and poor outcomes.
Clear delineation of the complex inflammatory cascades induced after SAH is necessary in order to develop targeted anti-
inflammatory therapies. Clinical
studies have demonstrated that CSF concentrations
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of the classical pro-
inflammatory cytokines interleukin-6, interleukin-8, interleukin-1β, tumor necrosis
factor-alpha, and MCP-1 (monocyte chemoattractant
protein-1) correlate with DCI and poor outcomes.154–157
Unfortunately, many early mechanistic studies in animal models have focused primarily on vasospasm
instead of neuronal cell death or behavioral outcome,
obscuring their relevance to translational application.
Within the last 15 years, this paradigm has begun to
shift, and the cellular and molecular mechanisms of
SAH-induced inflammation are emerging from animal
studies. We present these advances in the context of
the inflammatory cells, resident microglia, and peripheral leukocytes, which mediate host response to SAH
and react to inflammatory change within the CNS.

Cellular Mediators—Glia
Glial involvement in SAH pathology had been suspected since the establishment of free heme as a
toll-like receptor 4 (TLR4) activator.158 TLR4, a pattern
recognition receptor central to innate immune function,
is expressed in all myeloid-origin cells159; however, the
function of microglia as resident TLR4-expressing cells
makes them well positioned to respond first to TLR4-
heme interactions in the CNS. TLR4 expression was
shown to increase after SAH,160 but the evidence for
microglial participation in SAH pathology remained
speculative until a landmark paper from Hanafy demonstrated microglia-depleted mice have reduced vasospasm and neuronal apoptosis.161 The same study
showed neuronal apoptosis and vasospasm are diminished in TLR4 knockout mice early after SAH but evolve
to be driven by TLR4-independent mechanisms in the
delayed phase. The contribution of microglia to neuronal cell death after SAH was reaffirmed by Schneider
et al through selective depletion of microglia using a
ganciclovir-sensitive “suicide gene.”162 This study left
peripheral macrophages intact to differentiate between
resident and peripheral myeloid cell involvement. They
found that microglia-
depleted mice had decreased
neuronal cell death as far out as 9 days post-SAH.
Together, these studies clearly establish microglia as
critical mediators of neuroinflammation and neuronal
injury after SAH (Figure 2).
The precise molecular mechanisms of microglia action in the DCI phase remain elusive; the Hanafy study
demonstrated neuronal cell death is TLR4-dependent
only in the early brain injury phase. There are several
other proposed pathways that contribute to microglia-
mediated neuroinflammation after hemorrhagic stroke.
In cultured microglia cells, the inflammatory reaction
to thrombin exposure (ie, interleukin-6, tumor necrosis factor-
alpha, CCL2/MCP1 [chemokine ligand 2/
monocyte chemoattractant protein 1] production) is
muted by TGFβ1 (transforming growth factor beta 1)
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Figure 2. Mechanisms of inflammatory response after subarachnoid hemorrhage.
Subarachnoid hemorrhage elicits an inflammatory response from resident CNS glia directly through TLR4
and CD163 receptor signaling. Reactive microglia then contribute to inflammatory cytokine production,
vasospasm, and neuronal apoptosis. The endothelium of the cerebrovasculature also contributes to
inflammation by recruiting circulating leukocytes. Neutrophils, monocytes, and lymphocytes all enter the
CNS after SAH and promote vasospasm and inflammatory cytokine release. CD163 indicates cluster of
differentiation 163; CNS, central nervous system; SAH, subarachnoid hemorrhage; and TLR4, toll-like
receptor 4.

treatment.163 Further, the same study showed reactive
microglia express lower levels of TGFβ1, and human
patients with increased TGFβ1 after intracerebral hemorrhage had better outcomes at 90 days; These findings have yet to be replicated in humans after SAH, but
simvastatin therapy was found to induce lymphocytic
TGFβ1 expression in a rat model,164 suggesting there
could be similarities in TGFβ1’s actions. HMGB1 (high
mobility group box 1 protein is a nuclear protein that
regulates chromatin remodeling and gene transcription; however, it is also secreted as an inflammatory cytokine by myeloid lineage cells, including microglia.165
Neutralization of HMGB1 with a monoclonal antibody
attenuates microglial reactivity and improves neurological function after SAH.166 In humans, higher HMGB1
CSF concentrations are correlated with unfavorable
outcomes.156 Unfortunately, these studies are unable
to differentiate between microglia-derived and macrophage/monocyte-derived HMGB1, complicating their

interpretation. Future investigation should evaluate the
mechanisms of microglial involvement in the delayed
phase after SAH.

Cellular Mediators—Peripheral
Leukocytes
An association between peripheral immune response
and outcome after SAH has been observed for many
years,167 including recently when outcome measures
were updated to match the current consensus definition of DCI.143 Markers of both myeloid and lymphoid
lineage cells have also been directly observed in the
CSF and tissue near the subarachnoid space, implying
these cells could be directly involved with SAH pathology.154,168,169 Other correlational studies support this
notion by showing the degree of peripheral immune
reaction predicts outcome.140,141,170 One hypothesis to
explain this phenomenon is that peripheral immune
cells respond when the resident CNS macrophages
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(microglia) are overwhelmed by massive hemolysis following SAH. The baseline capacity of the CNS CD163
(cluster of differentiation 163)-haptoglobin scavenger
system is much lower than in the periphery and is easily saturated after SAH.171 Administration of haptoglobin
into the subarachnoid space has been shown to reduce vasospasm.172 Haptoglobin genotype also affects
hemoglobin affinity and outcome after SAH indicating
that the response after CD163-haptoglobin saturation
could be responsible for some of the detrimental effects.173,174 Cyclosporine A, an immunosuppressant
that acts primarily through T cells but also inhibits myeloid cell function,175 was used to target this immune
reaction but has resulted in mixed effects in underpowered trials and animal studies.176–179 Animals studies
have shown generally positive results from peripheral
myeloid cell depletion. Monoclonal antibody-mediated
neutralization of CD11b/CD18-positive cells resulted in
decreased vasospasm in rabbits and nonhuman primates.180,181 The limitation of these studies is the emphasis on vasospasm as an outcome measure rather
than DCI. The expression of CD11b/CD18 on multiple
cell types also limits their interpretation. A similar study
from Provencio et al improved on previous studies by
demonstrating improved functional outcome in addition to decreased vasospasm in mice after treatment
with anti-lymphocyte antigen 6 complex antibody.182
Lymphocyte antigen 6 complex is primarily expressed
on neutrophils but certain monocyte, macrophages,
and lymphocyte subpopulations also express this
marker.183 Taken together, these data show a strong
scientific premise for peripheral myeloid and lymphoid
cell involvement in the SAH pathology (Figure 2). More
studies with emphasis on DCI and functional outcome
are needed before translational therapies can be trialed in human patients.
By responding to inflammatory change on endothelial surfaces, circulating immune cells serve as
the link between vascular dysfunction, vascular inflammation, and systemic immune response. Cell
adhesion molecules (CAMs) are a family of proteins
that facilitate immune cell—endothelium interaction
after vascular injury.184 Increased CAM expression
after SAH is well-established, having been demonstrated in the serum and CSF of humans as well as
directly in the vascular and cerebral tissues of animal studies.185–187 A study by Polin et al showed several CAMs (intercellular adhesion module-1 [ICAM-1],
VCAM-1, and E-selectin) are upregulated in CSF after
SAH and E-selectin levels correlate with poor outcomes.188 Another study similarly showed P-selectin
but not ICAM-1, vascular CAM-1, or platelet endothelial CAM was increased in patients with low-grade
SAH and DCI.98 These studies suggest that the selectin subtype of CAMs may be more important in
the development of DCI than the immunoglobulin
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superfamily subtype (ICAM-1, vascular CAM-1, etc);
however, no interventional studies have proven a direct role. One study has shown E-selectin inhibition
decreases vasospasm in rodents.189 Treatments neutralizing ICAM-1 via antibody treatment have shown
decreased leukocyte infiltration, demonstrating the
putative mechanism of CAMs in DCI pathology.190–192
One of these studies coadministered an anti-CD18
(ICAM-1 ligand) antibody and found that vasospasm
was decreased more than with anti-
ICAM-
1 treatment alone, suggesting that inflammatory cells contribute to vasospasm in a partially CAM-independent
fashion.192 The use of vasospasm as outcome rather
than neurobehavioral function is a major limitation of
these studies; nonetheless, the entirety of the current
literature supports the hypothesis that peripheral immune cells respond to inflammatory changes in the
endothelium after SAH. More investigation into these
pathways with a focus on functional outcome is necessary to determine their utility as therapeutic targets.
Statins have been tested extensively owing to their
anti-
inflammatory effects independent of hepatic β-
Hydroxy β-methylglutaryl-CoA reductase inhibition.193
Some early single-center randomized controlled trials
with simvastatin194 and pravastatin136 showed reductions in vasospasm and DCI, encouraging more investigation into statin therapy. The largest trials to date
(STASH [Simvastatin in Aneurysmal Subarachnoid
Haemorrhage] and HDS-SAH [High-Dose Simvastatin
for Aneurysmal Subarachnoid Hemorrhage]), however,
demonstrated simvastatin does not improve outcomes
or reduce DCI.39,40

SPREADING DEPOLARIZATIONS
Physiology of Spreading Depolarizations
Spreading depolarizations, as the term implies, are
slowly propagating waves of almost complete membrane depolarizations in both neuronal and glial cells.
Usage of the terms “spreading depolarization” and
“spreading depression” often varies between authors
and disciplines; for the purposes of this review, we
consider “spreading depolarization” to best describe
the underlying biophysical phenomenon, “spreading
depression” to be its manifestation as decreased neuroelectric activity, and use the initialism “SD” to refer in
general to both spreading depolarizations and depressions. Spreading depressions were first discovered by
Leão in 1944 while studying epilepsy and he noted its
hyperemic effect on pial vasculature soon after.195,196 In
healthy brain tissue, SDs can be elicited by increasing
extracellular K+ concentrations to a point where passive ion channels open and overload the capacity for
ATP-dependent Na+, K+, and Ca2+ pumps to maintain
ion homeostasis.197 SDs are initiated by similar mechanisms in metabolically compromised brain tissue but
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can be more severe and longer lasting.198 Mechanisms
of SD propagation are still under intense investigation,
but it is generally accepted that passive diffusion of
extracellular K+ and glutamate provoke depolarization
in surrounding grey matter.198,199 A positive feedback
loop mediated by N-methyl-D-aspartate receptor-
and Ca2+ channel-dependent glutamate release and
other voltage-gated channels also seems crucial to
the self-sustaining nature of SDs.198 Because of their
uniqueness and powerful suppression of normal brain
activity, SDs have been studied extensively in the context of many neurological disorders and diseases including stroke.199

Spreading Depolarizations After SAH
SDs evoke a hyperemic response in healthy tissues
as a result of the increased metabolic demand during disrupted ion homeostasis.200 Injured or otherwise
compromised brain tissues are more prone to neurovascular uncoupling and often show hypoperfusion
after SDs (Figure 3).200 These depolarizations are also
sometimes referred to as “peri-ischemic depolarizations” or “cortical spreading ischemia,” although they
are functionally indistinguishable from SDs when they
spread into healthy tissue.201,202 Early investigation
into neuroelectric sequelae of cerebrovascular disease revealed that ischemic stroke induces multiple
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occurrences of SDs through the cortex.203 Just a few
years later, Dreier et al demonstrated that topical application of K+ and hemoglobin could induce SDs/
cortical spreading ischemia in rats.204 K+ cations and
free hemoglobin in the subarachnoid space are characteristic of hemolyzed red blood cells after SAH, leading to the hypothesis that SDs induced in this manner
might play a pathologic role in the poor outcomes are
SAH. Consistent with this notion, Dreier et al again
showed that “products of hemolysis” (K+ and hemoglobin added to artificial CSF) cause SDs and cortical
spreading ischemia in the cortex as well as massive
neuronal cell death and reactive gliosis (Figure 3).205
A landmark paper from the same group found that
SDs occur after SAH in humans and predict the development of DCI.206 Later studies also revealed that
clusters of SDs magnify the duration of tissue hypoxia
and that clustered SDs may be more important to DCI
pathology than isolated depolarizations.207,208 Further,
the correlation between SDs and DCI remains even
after the successful treatment of angiographic vasospasm.209 The totality of these studies, driven in large
part by the COSBID (Co-Operative Studies on Brain
Injury Depolarizations) Study Group, have revolutionized the conceptualization of DCI pathology. SDs and
related factors are now rightly at the forefront of investigation into improving SAH outcomes.
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Figure 3. Spreading depolarizations after subarachnoid hemorrhage and potential therapeutic targets.
Spreading depolarizations cause cerebral ischemia by increasing metabolic demand in injured tissue unable to compensate with
increased perfusion. SAH itself also promotes the development of spreading depolarizations by the release of K+ and glutamate from
extravasated erythrocytes and platelets. A couple of promising therapeutic agents to prevent spreading depolarizations/cortical
spreading ischemia are ketamine and cilostazol. Ketamine works through inhibiting NMDA receptors and the propagation of spreading
depolarizations. Cilostazol reduces ischemia by improving neurovascular response to depolarization. DCI indicates delayed cerebral
ischemia; NMDA, N-methyl-D -aspartate; and SAH, subarachnoid hemorrhage.
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Inquiry into treatments that target SDs/peri-ischemic
depolarizations to prevent DCI is still in its early
stages; nonetheless, several promising avenues of
investigation have been identified. Vasoactive drugs
can modulate the neurovascular response to SD and
prevent pathological hypoperfusion. The earliest work
was based on the finding from Dreier et al that inhibition of NOS produced similar SD effects as topical
hemoglobin application, implying that NO scavenging
and vasoconstriction by hemoglobin could be critical to transforming the hyperemic SD response into
a cortical spreading ischemia response.204 Treatment
with NO-
donors and NO-
independent vasodilators
reduced the ischemia/hypoperfusion after K+-induced
SDs.210 The same group of researchers also showed
nimodipine treatment reduces SD-induced ischemia
in rats.211 Years later, the phosphodiesterase enzyme3
inhibitor cilostazol was shown to reduce spreading ischemia after mimicked SAH-induced SDs (Figure 3).212
The same study tested cilostazol in a relatively small
number of human patients with aSAH and observed
a nonsignificant trend for decreased DCI, indicating a
larger clinical trial may be worthwhile. These studies
exemplify the interdependency between pathological
factors after SAH. Given the discrepancy in perfusion
response between healthy and injured tissues, SDs/
peri-ischemic depolarizations reveal vulnerabilities in
the cerebrovasculature that might not have otherwise
progressed far enough to cause DCI. The second
area of investigation into therapeutics is direct inhibition of SD propagation. N-methyl-D-aspartate receptors have long been known to play a pivotal role
in SD propagation in otherwise healthy tissue213–215;
thus, N-methyl-D-aspartate receptor antagonism was
a logical place to explore post-SAH therapies. A 2012
study analyzing various classes of sedatives and analgesics found that the N-methyl-D-aspartate receptor antagonist ketamine decreased the incidence of
SDs in patients with traumatic brain injury and SAH,
whereas midazolam increased SDs and propofol,
fentanyl, and morphine had no effect.216 More recent
studies have found that ketamine reduces SDs in a
dose-dependent fashion and can inhibit SD incidence
when started in patients with SAH who have already
had multiple SDs (Figure 3).217,218 Larger clinical trials
are needed to fully evaluate the efficacy of ketamine
in this context. The anticonvulsant valproate has also
been investigated based on its SD-inhibiting properties in healthy tissue.219,220 Valproate treatment was
found to reduce cerebral lesion growth after SAH
with and without added SD induction (topical potassium chloride application).221 To our knowledge, these
findings have yet to be replicated in human patients
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with SAH but still contribute to the mounting evidence
that blocking SD propagation could yield favorable
outcomes. Additionally, older treatments need to
be reassessed with respect to their effects of SDs.
As previously discussed, nimodipine reduces SD-
induced ischemia and it is tempting to assume this
occurs through inhibition of L-type calcium channels
in the smooth muscle of the cerebrovasculature; however, nimodipine can work in a vessel-independent
fashion to directly alter the ion flux/electrical response
to stress in neurons.222 This finding could help explain
why nimodipine reduces secondary ischemia after
SAH without reducing vasospasm.34,36,37 The scientific rationale for targeting SDs to reduce DCI is strong;
now the objective of the field is to conduct powerful
clinical trials in order to demonstrate a clear benefit in
patients.

CONCLUSIONS
Rigorous investigation into the pathophysiology of delayed cerebral ischemia is imperative to improve outcomes following SAH. The efficacy of current standard
of care is suboptimal and large trials of new therapeutics have failed to demonstrate benefit. We believe a
deeper understanding of DCI will lead to novel therapeutic strategies and improve the lives of those who
suffer from this devastating disease. The goal of this review was to assist in this endeavor by providing an up-
to-date examination of the literature in regard to 3 main
areas of DCI pathology: vascular dysfunction, inflammation, and spreading depolarizations. Moreover, we
pay special attention to the relationships between these
areas in order to gain an integrative perspective of DCI
and properly interpret study results. This analysis also
serves to accentuate the recent discoveries that are the
most promising candidates for clinical investigation.
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